Compared to the treatment of chemotherapy alone, PD-1 or PD-L1 inhibitors combined with chemotherapy significantly increased the risk of immune-related adverse events in TNBC patients, including serious pneumonitis, hypothyroidism, and adrenal insufficiency, but the incidences were relatively low. The gene discussed is PDCD1; the disease is pneumonitis.